Molecular Health signs up HudsonAlpha Institute for Biotechnology as new U.S. customer for MH Guide

• Molecular Health Guide (MH Guide) gains ground in important U.S. market
• MH Guide easily translates complex genetic data to support intelligent personalized medical decisions

Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company has signed up the HudsonAlpha Institute for Biotechnology (HudsonAlpha) as a new client for MH Guide. HudsonAlpha is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization.

MH Guide enables smarter patient care decisions based on deeper and broader biomedical information: Molecular pathologists and human geneticists can interpret genetic data derived from different technologies, such as next-generation sequencing, and create clinical reports that include drug information and variant classifications in minutes – easily, confidently, and accurately. HudsonAlpha plans to use MH Guide to elucidate detailed information on mutations found in patient tumor samples.

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: ”Molecular Health is increasing its footprint in the U.S. as we sign on important new clients for our products. We are delighted to welcome HudsonAlpha as a customer and look forward to contributing through MH Guide to the important work they are doing to advance science and healthcare.”

About MH Guide
MH Guide, the gold standard in genomic data processing and analysis, is a rich bioinformatics platform, allowing medical professionals to analyze variants in the context of a patient’s cancer disease or predisposition to support identification of the potentially most effective treatments or disease predispositions. Molecular Health integrates private and publicly available databases, peer-reviewed scientific literature, and genome studies to extract salient information categorized by gene variant, disease, indication, cancer pharmacogenetics, and other relevant clinical classifiers. The stringent quality process Molecular Health follows to annotate and create its medical content is what sets MH Guide apart. Clients retain ownership of all data at all stages of the analysis, including the analysis results, which can be provided in a variety of digital formats, and have access to all source evidence for the annotations provided by the system. MH Guide is the first software product approved as an IVD medical device by the EU and is currently eligible for reimbursement in the EU.

About Molecular Health
Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.
For more information, visit www.molecularhealth.com.